Rachel Weiszer

Rachel Weiszer serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through advanced scientific infrastructure and technology. She manages complex acquisitions centered on custom computer programming services, ensuring that cutting-edge computational tools, genomic data analysis platforms, and precision medicine systems are procured in alignment with NIH’s scientific priorities. Her work directly enables high-performance research environments by securing software solutions that integrate large-scale biological datasets, support machine learning models, and enhance data interoperability across distributed laboratory networks. Her primary contractor relationships are anchored with Roche Diagnostics Corporation, a leading provider of molecular diagnostics and bioinformatics solutions, reflecting a strategic preference for industry partners with deep expertise in oncology data systems and clinical-grade software development. She routinely engages with vendors capable of delivering secure, scalable, and FDA-aligned computational pipelines, often requiring compliance with HIPAA, 21 CFR Part 11, and NCI’s data governance standards. Her contracting approach emphasizes performance-based outcomes, long-term vendor collaboration, and technical validation of software deliverables. Weiszer’s procurement portfolio is predominantly non-set-aside, with 75% of acquisitions conducted under full and open competition, while 25% are structured as total small business set-asides under FAR 19.5. This balance reflects a deliberate strategy to leverage both industry scale and innovation from small businesses, particularly those with specialized capabilities in bioinformatics and health data analytics. Her socioeconomic contracting patterns prioritize qualified small businesses with proven technical credentials in computational biology and clinical informatics. Her primary NAICS classification is 541511 (Custom Computer Programming Services), underscoring a singular focus on bespoke software development for cancer research applications. She procures tailored solutions including data warehousing systems, algorithmic analysis tools, cloud-based genomic processing platforms, and AI-driven diagnostic support systems—all critical to advancing NCI’s translational research agenda.